Aeterna Zentaris NDA for Macimorelin Acetate in AGHD Accepted for Filing by FDA

Aeterna Zentaris

today announced that the U.S. Food and Drug Administration ("FDA") has accepted for filing the Company's New Drug Application ("NDA") for its ghrelin agonist, macimorelin acetate, in Adult Growth Hormone Deficiency ("AGHD"). The acceptance for filing of the NDA indicates the FDA has determined that the application is sufficiently complete to permit a substantive review.